CVS HEALTH Corp: Form 10-K for the period ended Dec 31, 2014
Filed with the SEC on Feb 10, 2015 and accepted by EDGAR at Feb 10, 2015, 16:48 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2014-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2014-10-01 to 2014-12-31 | $37.05bn | us-gaap:Revenues |
| Revenue | 12 months2014-01-01 to 2014-12-31 | $139.37bn | us-gaap:Revenues |
| Cost of revenue | 12 months2014-01-01 to 2014-12-31 | $114.00bn | us-gaap:CostOfRevenue |
| Gross profit | 3 months2014-10-01 to 2014-12-31 | $6.63bn | us-gaap:GrossProfit |
| Gross profit | 12 months2014-01-01 to 2014-12-31 | $25.37bn | us-gaap:GrossProfit |
| Operating income | 3 months2014-10-01 to 2014-12-31 | $2.32bn | us-gaap:OperatingIncomeLoss |
| Operating income | 12 months2014-01-01 to 2014-12-31 | $8.80bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2014-01-01 to 2014-12-31 | $615.0m | us-gaap:InterestExpense |
| Income tax | 12 months2014-01-01 to 2014-12-31 | $3.03bn | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2014-10-01 to 2014-12-31 | $1.32bn | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2014-10-01 to 2014-12-31 | $1.14 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2014-01-01 to 2014-12-31 | $3.96 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2014-10-01 to 2014-12-31 | $1.15 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2014-01-01 to 2014-12-31 | $3.98 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2014-01-01 to 2014-12-31 | 1,169,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2014-01-01 to 2014-12-31 | $8.14bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2014-01-01 to 2014-12-31 | $2.14bn | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 12 months2014-01-01 to 2014-12-31 | $1.29bn | us-gaap:PaymentsOfDividends |
| Share repurchases | 12 months2014-01-01 to 2014-12-31 | $4.00bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2014-12-31 | $2.48bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2014-12-31 | $25.98bn | us-gaap:AssetsCurrent |
| Total assets | At period end2014-12-31 | $74.25bn | us-gaap:Assets |
| Current liabilities | At period end2014-12-31 | $19.03bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2014-12-31 | $11.70bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2014-12-31 | $575.0m | us-gaap:LongTermDebtCurrent |
| Short-term borrowings | At period end2014-12-31 | $685.0m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2014-12-31 | $37.96bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000064803-15-000008. Last ingested by Listed: Nov 6, 2026, 17:47 ET. Listed shows no prices and gives no investment advice.